Tavaborole · TAVABOROLE 43.5 mg/mL · Solution · Topical · Viona Pharmaceuticals Inc
NDC 72578-0102-04 · 1 BOTTLE, WITH APPLICATOR in 1 CARTON / 10 mL in 1 BOTTLE, WITH APPLICATOR · ANDA · View full market →
7 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 12% over the past year, to $3.49 per mL. A Class II recall hit this product in the past year (Viona Pharmaceuticals Inc). Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Alembic Pharmaceuticals Inc. | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Chartwell RX, LLC | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Cipla USA Inc. | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Viona Pharmaceuticals Inc | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Tavaborole — NDC 72578-0102-04," retrieved September 3, 2026, https://drugdashboards.com/drug/72578010204.
Free to cite with attribution — see how the data is put together.